论文部分内容阅读
近几年来,利用抑癌基因治疗原发性肝癌逐渐成为研究的热点之一,重组人p53腺病毒(rAd-p53)制品治疗原发性肝癌也越来越受到高度关注。本文通过总结近几年这方面的研究进展,以评价其临床应用价值与发展前景。
In recent years, the use of tumor suppressor genes in the treatment of primary liver cancer has gradually become one of the research hotspots. Recombinant human p53 adenovirus (rAd-p53) products have also received increasing attention in the treatment of primary liver cancer. This article summarizes the research progress in this area in recent years to evaluate its clinical application value and development prospects.